# Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

> **NCT03228186** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Pevonedistat
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03228186
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-05
- **Primary completion:** 2021-11-04
- **Final completion:** 2021-11-04
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Pharmaceutical company discontinued the study drug.
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03228186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03228186, "Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03228186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*